Altorki NK et al. IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC). ESMO 2023;Abstract 1264MO.

Awad MM et al. Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. ESMO 2023;Abstract 1261O.

Cascone T et al. CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. ESMO 2023;Abstract LBA1.

Cho BC et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. ESMO 2023;Abstract LBA14.

Cho BC et al. Durvalumab ± tremelimumab + chemotherapy in 1L metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON. WCLC 2023;Abstract P2.06-05.

Cho BC et al. Sacituzumab govitecan + pembrolizumab in 1L metastatic non-small cell lung cancer: Preliminary results of the EVOKE-02 study. WCLC 2023;Abstract OA05.04.

Clarke JM et al. CodeBreaK 101: Safety and efficacy of sotorasib with carboplatin and pemetrexed in KRAS G12C-mutated advanced NSCLC. WCLC 2023;Abstract MA06.05.

Felip E et al. IMpower010: Exploratory analysis of tumour mutational burden and disease-free survival with adjuvant atezolizumab in NSCLC. WCLC 2023;Abstract MA11.08.

Filippi ARR et al. Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study. ESMO 2023;Abstract LBA62.

Gadgeel S et al. 5-year survival of pembrolizumab plus chemotherapy for metastatic NSCLC with PD-L1 tumor proportion score <1%. WCLC 2023;Abstract OA14.05.

Gandara DR et al. Predictive utility of patient-reported outcomes for survival in 1st-line treated patients with aNSCLC in EMPOWER-Lung 1 and 3. WCLC 2023;Abstract MA05.11.

Ganti AK et al. The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study. ASCO 2023;Abstract 8516.

Garassino MC et al. Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6. ESMO 2023;Abstract LBA61.

Garassino MC et al. KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ESMO 2023;Abstract LBA65.

Girard N et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase 3 global study. ESMO 2023;Abstract LBA5.

Herbst RS et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). ASCO 2023;Abstract LBA3.

Janne P et al. Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2). WCLC 2023;Abstract PL03.13.

Janne P et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer: Primary results of DESTINY-Lung02. WCLC 2023;Abstract MA13.10.

Johnson M et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: A subgroup analysis of a phase 1/2 study. WCLC 2023;Abstract OA05.05.

Johnson M et al. Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01. ESMO 2023;Abstract 1319MO.

Kim TM et al. Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following 1L osimertinib: INSIGHT 2 primary analysis. WCLC 2023;Abstract OA21.05.

Le X et al. A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). ESMO 2023;Abstract LBA71.

Leal T et al. TTFields and immune-checkpoint inhibitor in metastatic non-small cell lung cancer: PD-L1 subgroups in the phase 3 LUNAR study. WCLC 2023;Abstract OA22.05.

Lisberg AE et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. ESMO 2023;Abstract LBA12.

Loong HHF et al. Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. ESMO 2023;Abstract LBA4.

Makharadze T et al. Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3. ESMO 2023;Abstract 1438P.

Middleton G et al. A phase II trial of ceralasertib and durvalumab in advanced non-small cell lung cancer (NSCLC) with and without RAS mutations: Results of NLMT arm J. WCLC 2023;Abstract MA06.06.

Mitsudomi T et al. Surgical outcomes with neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in resectable NSCLC (AEGEAN). WCLC 2023;Abstract OA12.05.

Nassar AH et al. Consolidation EGFR-tyrosine kinase inhibitor (TKI) vs durvalumab vs observation in unresectable EGFR-mutant stage III NSCLC. WCLC 2023;Abstract MA16.11.

Papadopoulos KP et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced/mNSCLC: Initial results from phase 1b TROPION-Lung04. WCLC 2023;Abstract OA05.06.

Passaro P et al. Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. ESMO 2023;Abstract LBA15.

Paz-Ares L et al. Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study. ESMO 2023;Abstract LBA92.

Planchard D et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. ESMO 2023;Abstract 1321MO.

Peters S et al. Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC. ESMO 2023;Abstract LBA64.

Peters S et al. Real-world outcomes with durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC (PACIFIC-R). WCLC 2023;Abstract OA17.03.

Planchard D et al. FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. ESMO 2023;Abstract LBA68.

Pulla MP et al. Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression. ESMO 2023;Abstract LBA57.

Ramalingam SS et al. Six-year survival and HRQoL outcomes with 1L nivolumab + ipilimumab in patients with metastatic NSCLC from CheckMate227. WCLC 2023;Abstract OA14.03.

Reck M et al. Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. ESMO 2023;Abstract LBA59.

Solomon BJ et al. ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). ESMO 2023;Abstract LBA2.

Spicer JD et al. Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). ESMO 2023;Abstract LBA56.

Yu HA et al. Patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01. WCLC 2023;Abstract OA05.03.